A month after announcing that the FDA had slapped a clinical hold on its phase 1-ready, gene-edited CAR-T, Beam Therapeutics is shedding more light on the move.

Nearly a decade after reeling in the first FDA nod allowing its deep brain stimulation technology to help treat major depressive disorder, BrainsWay has doubled back with another agency-cleared depression treatment.

The race to develop an anticoagulant that could better prevent secondary strokes is heating up, or cooling down, depending on how you look at it. The state of play is now clearer than it was a few days ago, after dueling Big Pharmas presented new phase 2 data.

Scientists have discovered a new druggable pathway that may boost beta amyloid clearance, holding the potential to be used to help prevent Alzheimer’s dementia in humans.

Though the ongoing recall of approximately 5.5 million of Philips’ respiratory devices—the bulk of them CPAP machines—has dominated most of the last year’s headlines about the medtech giant, it’s not the only respiratory recall on the company’s plate.

Studies have shown that heart failure—which affects about 6.2 million adults in the U.S. alone—may shorten life expectancy by an average of 10 years and that only about half of those with the condition will live for another five years after diagnosis.

Despite CAR T-cell therapies’ high efficacy against certain blood cancers, many patients can relapse, and solid tumors simply don’t respond to existing options. That’s mainly because tumors develop various tactics that can exhaust or dumb T cells.

An artificial intelligence program developed by researchers at Stanford University was able to streamline ultrasound exams of the heart—to the point where trained cardiologists couldn’t tell whether the initial assessments came from a machine.

Getting a clear picture of the beating heart has always been a challenge. The artificial intelligence developer UltraSight hopes to make it much easier by giving clinicians a computer-guided helping hand.

Takeda is leaving the coop, handing the rights of two Finch eggs back to the microbiome-focused biotech.